20 / 34
Volume 9
Journal of Neurology and Neuroscience
ISSN: 2171-6625
Page 62
JOINT EVENT
July 23-24, 2018 Birmingham, UK
&
24
th
International Conference on
Neuroscience and Neurochemistry
26
th
Edition of International Conference on
Clinical Psychology and Neuroscience
Efficacy and safety of clobazam in a pediatric refractory epilepsy population less than two years of age
Ersida Buraniqi
1, 2
, Xiaofan Wang
1
, Fatemeh Mohammadpour Touserkani
1
, Kush Kapur
1
and
Tobias Loddenkemper
1
1
Harvard Medical School, USA
2
Mayo Clinic, Rochester, USA
Aim:
To describe our experience with the efficacy and safety of clobazam in refractory epilepsy in a large population of children
less than two years of age.
Methods:
We retrospectively reviewed all patients between 0 and 2 years of age at Boston Children’s Hospital from October
2011 to December 2016. We included patients who were treated with clobazam for refractory epilepsy, and who had a follow-
up visit at least one month after starting clobazam. Response to clobazam was defined as >50% reduction in seizure frequency
at the time of last follow-up visit as compared to baseline.
Results:
155 patients received clobazam, of which 116 [median age 12 months, IQR (p25-p75) 8-16 months] had full follow-
up data ≥1 month after starting clobazam. Median follow-up age was 14 months [IQR (p25-p75) 9-18 months]. At the time of
clobazam initiation, 31/116 (27%) patients were on one antiepileptic drug (AED), 52/116 (45%) patients were on two AEDs,
and 26/116 (22%) patients were on 3 or more AEDs. 7/116 (6%) patients received clobazam monotherapy. Overall response
rate was 33% (38/116) with a median seizure reduction of 75%. 18 (16%) patients had ≤50% reduction, 14 (12%) had no
change and 16 (14%) had worsening of seizure frequency. 30 (26%) patients became seizure free. 8 (7%) patients discontinued
clobazam.
Conclusions:
Clobazam is both well tolerated and effective in reducing seizure frequency in pediatric patients less than two
years of age with refractory epilepsy.
ersidaunivers@gmail.comJ Neurol Neurosci 2018, Volume 9
DOI: 10.21767/2171-6625-C2-012